RxDoctor Payments Data

Anuruddha Walaliyadda, MD

Internal Medicine · West Haven, CTNPI 1568468239

Payments from drug & device makers

$579in general payments, 2019–2025

Across 13 payments — averaging $44.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$329
  • Cardinal Health 200 LLC$114
  • Sun Pharmaceutical Industries Inc.$32
  • Avanir Pharmaceuticals, Inc.$23
  • Sumitomo Pharma America, Inc.$21
  • Teva Pharmaceuticals USA, Inc.$21
  • plus $40 from 2 others

What the payments were for

  • Food & beverage$579100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$579 in reported general payments places this provider in the 70th percentile of 2,067 internal medicine providers in Connecticut.

See all internal medicine providers in Connecticut

Medicare billing

Part B allowed, 2024
$57,290
Medicare patients
347
Services billed
435

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban1,435$349,368
BiktarvyBictegrav/Emtricit/Tenofov Ala38$154,663
TivicayDolutegravir Sodium75$127,014
IngrezzaValbenazine Tosylate11$91,753
XareltoRivaroxaban233$52,783
GenvoyaElviteg/Cob/Emtri/Tenof Alafen11$42,614
FarxigaDapagliflozin Propanediol120$37,566
JardianceEmpagliflozin157$32,349
ProcritEpoetin Alfa40$31,928
TradjentaLinagliptin169$30,460
PrezcobixDarunavir/Cobicistat20$24,173
OzempicSemaglutide20$23,092
Breo ElliptaFluticasone/Vilanterol54$22,957
Trelegy ElliptaFluticasone/Umeclidin/Vilanter37$21,004
PifeltroDoravirine11$20,353

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$329$91,75311 claims
AstraZenecaFarxiga$20$37,566120 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,067 internal medicine providers in Connecticut.

Other internal medicine in West Haven

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →